Background: Severe fever with thrombocytopenia syndrome bunyavirus (sftsv) is an emerging tick-borne rna virus recently identified as the pathogen that causes severe fever with thrombocytopenia syndrome (sfts) in china. the existing commercial nucleic acid testing (comnat) assay with a relatively high claimed limit of quantitative detection (loqd) is not capable of sensitive detection and quantitation of sftsv. Thus, a new real-time reverse transcriptase (rt)-pcr assay with improved sensitivity is needed for clinical diagnosis; it could also be used to screen blood donors if necessary. Materials and methods: We developed a new sftsv rt-pcr nat assay (newnat). About 129 plasma samples from 93 suspected sfts patients with typical clinical symptoms were tested using an anti-sftsv total antibody elisa and both comnat and newnat. The test performance of the two nat assays was evaluated and compared. Results: The newnat had a lower limit for quantitative testing compared to comnat. Twelve samples were comnat negative but newnat positive. Out of 35 suspected sfts patients who were comnat negative and anti-sftsv total antibody negative, four tested positive by the newnat assay and one of these four seroconverted within 2-4 days after testing newnat positive. A high correlation was observed between the cts of the newnat and comnat assays. Conclusion: The newnat assay was sensitive for quantitative detection of sftsv and may be applicable to clinical diagnosis and studies of the need for blood donor screening.
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| INTRODUCTION
Severe fever with thrombocytopenia syndrome bunyavirus (SFTSV) is a newly identified tick-borne pathogen that causes severe fever with thrombocytopenia syndrome (SFTS) initially reported from rural areas in central and eastern China with high initial fatality rates of 10 to 30%. 1 The SFTSV epidemic has been expanding in China, 2 while similar infection cases have been reported in Japan 3 and Korea, 4, 5 and the Heartland virus with close phylogenetic relationships to SFTSV was detected in the United States, 6 indicating possibly globally epidemics.
Effective methods of SFTSV detection are urgently needed for clinical diagnosis and disease control, as well as assessment of risk of SFTSV transmission by blood transfusion. Laboratory testing strategies to detect SFTSV infection have been rapidly provided for clinical diagnosis using serology-based screening by enzyme-linked immuno-commercial NAT (comNAT) assay based on one-step RT-PCR was developed and has been applied in epidemiological investigations. 8, 9 However, over 30% of patients with suspected clinical features of SFTS could not be confirmed by laboratory testing. 9 The cut-off Ct for the comNAT assay (the only commercial NAT assay for detection of 10 The assay is a double-antigen sandwich ELISA to detect SFTSV-specific antibodies binding to SFTSV recombinant nucleocapsid protein. 7 The sensitivity and specificity of ELISA assay were both 99.9% given by the manufacturer. (Table 1) The SFTSV RNA equivalents of 10 TCID 50 /mL were 4960 copies/mL, given by the manufacturer of comNAT assay. 
| Real-time RT-PCR to detect SFTSV RNA using newNAT

| Statistical analysis
Descriptive and correlation analyses were conducted by "XY correlation" analysis using GraphPad Prism Version 6.01 software (GraphPad software Inc., La Jolla, CA). Comparisons between the comNAT and the newNAT assays were assessed using ANOVA (for viral load and Cts) and chi-square or Fisher's exact tests (for nonparametric outcomes).
P < 0.05 was considered statistically significant.
3 | RESULTS
| comNAT and ELISA testing of clinical samples
The 129 clinical samples were classified into four groups by ELISA and comNAT testing, as summarized in Table 2 : (1) Twenty-three samples were positive by both comNAT and ELISA; (2) Fourty-six samples were comNAT positive/ELISA negative; (3) Nine samples were comNAT 
| Performance evaluation of the newNAT assay
The standard curve and amplification plots of the new real-time PCR assay were evaluated to determine reproducibility, efficiency, and dynamic range. The linear correlation (R 2> 0.99) between Ct value and SFTSV RNA input was high (Fig. 1) .The assay had 100% amplification efficiency, based on the slope of the standard curve. Furthermore, good reproducibility was observed for the five quantitative standards, with standard deviations of the Cts ranging from 0.23 to 0.53 (Table 3 ).
The lower limit for quantitative testing for the newNAT assay was estimated to be 20 PFU/mL corresponding to the concentration of SFTSV detectable at a Ct of 38.8. The primers and probe of S segment used in study have been systematically proved by group from National
Institute for Viral Disease Control and Prevention, China CDC having no cross-react with other bunyaviruses or virus that could cause similar symptoms. 13 Further in this study, the newNAT was also used to test against virus RNA extract of Dengue virus serotype one and two and Chikungunya fever virus, and no positive results were obtained. Assuming that the two PCR reactive samples out of 9960 blood donor samples tested in a previous study 10 were false positive, the specificity of the assay was estimated to be 99.98%.
| Testing of clinical samples with the newNAT assay
Eighty-one samples collected from 61 patients were SFTSV RNA positive by the newNAT, including 40 paired samples from 20 patients Of 36 SFTS suspected patients with two collected samples, 20 patients were newNAT positive on both of their samples. (Table 5) Nine of these 20 patients were ELISA negative on both visits, four seroconverted over a 2-4 day interval (i.e., between 1DOH and 3-5DOH), and seven were ELISA positive on both visits. One patient was ELISA positive/newNAT negative on both visits (Patient ID: 69).
For the four seroconverted patients, one (Patient ID: 94) tested newNAT positive but comNAT negative. No difference in viral loads was found between 1DOH and 3-5DOH (P = 0.57).
| Comparison of quantitative assay performance of comNAT and newNAT
The correlation of the Cts between comNAT and newNAT is displayed in Fig. 3 . The Cts for selected clinical samples (n = 22) ranged from 25 to 34. Significant correlation between the two assays was observed (P < 0.0001). To evaluate the sensitivity of the comNAT assay relative to the newNAT assay, the claimed LOQD of quantitative standard of the comNAT assay was diluted to 10 TCID 50 /mL and amplified using the newNAT assay with its corresponding five quantitative standards (ranging from 2 × 10 5 to 20 PFU/mL). Based on this analysis, the claimed LOD of the comNAT assay (10 TCID 50 /mL or 4960 copies/mL of SFTSV RNA) was estimated to be 387 ± 27 PFU/mL, the equivalent relation of PFU/mL and SFTSV RNA copies/mL can be calculated as:
1 PFU/mL ≈ 13 copies/mL. Four comNAT and ELISA negative patients tested positive by the newNAT, although 33% (31/93) of suspected SFTS patients remained negative by both the commercial and new NAT assays and ELISA testing. We speculate that the 31 anti-SFTSV total antibody and RNA negative patients might be infected by other pathogens, since the pathogens in Xinyang and its neighboring regions, such as Anaplasma phagocytophilum 14 and Orientia tsutsugamushi, 15 result in very similar symptoms such as fever, malaise and thrombocytopenia. 16 We also Out of 36 patients with two collection times, 20 were positive by SFTSV RNA by newNAT; nine of these were ELISA negative on both visits, four seroconverted over a 2-4 day interval and seven were ELISA positive on both visits.; 1DOH: The 1st day of hospitalization; 3-5DOH: The 3rd to 5th day of hospitalization. and PFU/mL for newNAT), we were able to perform a direct comparison by serially diluting the comNAT standard and assuring it using the newNAT assay. Given that we observed good correlation between the Cts of the two NAT assays when we tested the samples with lower viral load (e.g., Ct>35) (Table 4) , it is clear that a higher Ct cutoff for the comNAT assay would have resulted in more cases scoring positive. However, we did not further explore a higher Ct cutoff for the comNAT for two reasons:
(i) the more constrained quantitative range listed in the comNAT product insert and verified in this study implies that detection on low viral load samples might not be as reliable as the newNAT and
(ii) when we formerly applied the comNAT assays for SFTSV RNA screening in the low risk blood donor population, we found that abnormal non-specific amplifications were commonly observed when the comNAT Ct was >35 (i.e., some samples were amplified with Ct of 38-39 in the comNAT, but were negative by newNAT).
Thus, further evaluation would be needed to determine the impact of increasing the comNAT cutoff value on that assay's specificity.
A probit analysis of the analytic sensitivity of the newNAT PCR assay was reported in our previous study. 10 By multiple testing with newNAT on serial dilutions of the same quantitative standard used in this study from 10 PFU/mL to 0.1 PFU/mL, the 95% limit of detection for the newNAT was 5.4 PFU/mL and the 50% limit of detection was 0.8 PFU/mL. 18 It could be speculated that higher sensitivity for the newNAT assay relative to comNAT may result from the difference in PCR procedures between the two assays. The comNAT assay is based on a one-step RT-PCR with 20 µL reaction volume, whereas the new NAT assay employed a two-step RT-PCR with larger RT (120 µL) and PCR (75 µL) reaction volumes. In addition, the high specificity of the newNAT (previously reported as 99.98%) permits the test to use a higher Ct value as a cutoff, thus contributing to its greater sensitivity compared to comNAT.
The newNAT assay for SFTSV has been applied in large-scale screening among blood donors from endemic region (Xinyang, China) using four-sample mini-pools. After testing of 2490 pools (9960 samples from blood donors) and further resolution testing on reactive pools, two suspected SFTSV RNA positive donors with extremely low viral load (mean Cts of 39.3 and 39.7, respectively, viral loads <20PFU/ mL) were identified. The study of SFTSV NAT performance on pools from blood donors documented the sensitivity and specificity of the newNAT assay and suggested that the newNAT assay was applicable to SFTSV surveillance and potentially blood screening in endemic regions after further optimization.
One limitation of this study is that we could not rule out whether the five newNAT positive/comNAT negative samples in ELISA negative patients were false positive by newNAT, since there was no follow-up sample to test for seroconversion. However, based on the application of newNAT to SFTSV screening among blood donors (see above), the specificity of the new NAT assay is greater than 99.9%, which reduces the likelihood of false positives in this study. A second limitation is that, compared with the comNAT assay, the testing procedure of the newNAT is more cumbersome with two-step real time RT-PCR; In general, the assay may need to be modified for automation to reach the demand of potential high-throughput screening at blood centers should donor screening be warranted.
Furthermore, the low LOQD may require higher facility standards and stricter experimental procedures in the laboratory to avoid PCR contamination. For clinical diagnosis, however, the newNAT assay demonstrated sensitivity in detection of samples with viral loads lower than the LOQD of the comNAT assay.
In conclusion, we have developed and validated a sensitive and 
